What is the proper method to discontinue heparin therapy and when is it necessary to initiate an alternative anticoagulant?

Discontinuing Heparin: Method and Transition Strategy

Simply stop the heparin infusion immediately when discontinuation is indicated; whether you need to start an alternative anticoagulant depends entirely on the patient's underlying thrombotic risk and the reason heparin was prescribed in the first place. 1

When to Discontinue Without Bridging

For low-risk patients or those undergoing brief procedures (≤1 week interruption), you can stop heparin without substituting another anticoagulant. 2

• In atrial fibrillation patients without mechanical valves, interrupting anticoagulation for up to 1 week for surgical or diagnostic procedures that carry bleeding risk is reasonable without heparin substitution. 2
• For procedures with low bleeding risk (e.g., cataract surgery), no changes in anticoagulation are needed at all. 3
• If heparin was used only for procedural anticoagulation and the patient has no ongoing thrombotic indication, simply discontinue it. 1

When Alternative Anticoagulation Is Mandatory

You must transition to an alternative anticoagulant if the patient has high thrombotic risk or if heparin-induced thrombocytopenia (HIT) is suspected or confirmed. 1

High Thrombotic Risk Scenarios Requiring Bridging:

• Mechanical heart valves (especially mitral position or older ball/cage models) 2, 4
• Recent venous thromboembolism (<3 months) plus thrombophilia 3
• Atrial fibrillation with prior embolic stroke 2, 4
• Recent thromboembolic event (<3 months) 5
• Active HIT or recent HIT (<1 month) 5

Bridging Protocol for High-Risk Patients

Step 1: Stop Heparin Immediately

Discontinue the heparin infusion promptly. 1

Step 2: Choose Your Bridging Agent Based on Clinical Context

For Non-HIT Patients:

Low-molecular-weight heparin (LMWH) is the preferred bridging agent for most high-risk patients. 3, 4

• Start therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg subcutaneously twice daily or nadroparin 70 U/kg twice daily) within 12–24 hours after stopping heparin. 3
• Continue LMWH until oral anticoagulation (warfarin) achieves therapeutic INR (2.0–3.0) for >48 hours. 4
• Warfarin should be started on day 1 or 2 after the procedure (when hemostasis is adequate) at the pre-operative maintenance dose plus a 50% boost for two consecutive days. 3

For HIT or Suspected HIT Patients:

All heparin must be stopped immediately and replaced with a non-heparin anticoagulant, even if thrombocytopenia is isolated without thrombosis. 6, 7, 1

Recommended non-heparin alternatives (in order of preference based on availability and renal function): 5, 7

1. Argatroban (direct thrombin inhibitor):

   • Preferred in renal insufficiency 7
   • Stop infusion 4 hours before any procedure 5
   • Half-life ~50 minutes 5

2. Bivalirudin (direct thrombin inhibitor):

   • Stop infusion 2 hours before any procedure 5
   • Half-life 20–30 minutes 5

3. Fondaparinux (Factor Xa inhibitor):

   • Dosed by weight: 5 mg (<50 kg), 7.5 mg (50–100 kg), 10 mg (>100 kg) subcutaneously once daily 8
   • Last injection >36 hours before surgery 5
   • Avoid in severe renal impairment (CrCl <30 mL/min) 8

4. Danaparoid (heparinoid with anti-Xa activity):

   • Stop infusion or last subcutaneous injection >36 hours before surgery 5
   • Not available in North America 9

Use therapeutic-intensity dosing, not prophylactic doses, for all non-heparin anticoagulants in HIT. 6, 10

Step 3: Transition to Oral Anticoagulation (If Long-Term Therapy Needed)

For patients requiring prolonged anticoagulation after heparin discontinuation: 8

Warfarin Transition:

• Never start warfarin during acute HIT or until platelets recover to >150 × 10⁹/L. 7, 11
• Begin warfarin at low dose (maximum 5 mg) and overlap with the non-heparin anticoagulant for at least 5 days until INR is therapeutic (2.0–3.0) for >48 hours. 4, 7
• If warfarin was already started when HIT is diagnosed, administer vitamin K to reverse it. 7, 11

Direct Oral Anticoagulants (DOACs):

DOACs are now preferred over warfarin for most indications and can replace parenteral non-heparin anticoagulants once platelets recover in HIT patients. 5, 8, 10

• Rivaroxaban: 15 mg orally twice daily for 21 days, then 20 mg once daily 8
• Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily 8
• DOACs should not be started until platelet counts have recovered; they are not immediate replacements for parenteral agents. 8

Critical Monitoring During Discontinuation

Monitor platelet counts closely if heparin was used for >4 days. 1

• If platelet count falls below 100,000/mm³ or recurrent thrombosis develops, immediately discontinue heparin, evaluate for HIT, and start a non-heparin anticoagulant. 1
• HIT can occur up to several weeks after heparin discontinuation, so remain vigilant for delayed presentations. 1

Common Pitfalls to Avoid

• Never use warfarin alone without overlapping parenteral anticoagulation for acute VTE; bridging is mandatory. 4, 8
• Do not start warfarin during acute HIT—it can cause venous limb gangrene and skin necrosis. 7, 11, 9
• Aspirin does not provide equivalent protection to anticoagulants in high-risk patients; it is only for low-risk atrial fibrillation or contraindications to anticoagulation. 2, 8
• Prophylactic-dose anticoagulation is insufficient when therapeutic anticoagulation is indicated. 6, 8
• Do not transfuse platelets in HIT unless life-threatening bleeding occurs. 5
• Fondaparinux and danaparoid have long half-lives (17–24 hours); if urgent surgery is needed, consider switching to argatroban or bivalirudin. 5